Business Wire

Samsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF Biosimilars BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) at EULAR 2018

Del

Samsung Bioepis Co., Ltd. and Biogen (Nasdaq:BIIB) today announced pooled analysis results of three anti-tumor necrosis factor (anti-TNF) biosimilars – BENEPALI™ (SB4, etanercept biosimilar), FLIXABI™ (SB2, infliximab biosimilar), and IMRALDI™ (SB5, adalimumab biosimilar) – which will be presented at the Annual European Congress of Rheumatology (EULAR 2018) held June 13–16 in Amsterdam, Netherlands.

“Since BENEPALI and FLIXABI launched more than two years ago, they have played an increasingly important role in widening access to life-enhancing treatment options for patients and healthcare systems across Europe,” said Chul Kim, Head of Clinical Sciences Division, Samsung Bioepis. “We remain committed to advancing our strong pipeline of biosimilar candidates, so that more patients and healthcare systems across the region will be able to benefit from biosimilars.”

Data from three separate Phase III randomized, double-blind studies compared the efficacy and safety of BENEPALI in reference to etanercept (ETN); FLIXABI to infliximab (INF); and IMRALDI to adalimumab (ADL). The data were pooled and analyzed to assess the impact of anti-drug antibodies (ADAbs) on efficacy and tolerability, as well as radiographic progression by disease activity state.

Each clinical study had similar study designs and population demographics, and the same primary endpoint of ACR20 response rate. All patients included in the studies had been diagnosed with moderate to severe rheumatoid arthritis (RA) despite previous methotrexate treatment.

“This analysis presents a unique opportunity to compare the efficacy of three anti-TNFs in slowing the progression of joint erosion in patients with moderate to severe RA, as measured by radiographic progression,” said Ian Henshaw, Global Head of Biogen’s Biosimilar Unit. “We look forward to continuing to collaborate with Samsung Bioepis to provide guidance on treatment algorithms and as we work toward our goal of expanding access to biosimilars for patients who may benefit in Europe and around the world.”

Immunogenicity data from 1,710 patients with RA pooled from the three studies revealed that the incidence of ADAb was comparable between the biosimilars and their reference products – indicating that the biosimilars were equally effective as their biologic counterparts. In addition, efficacy and injection site reactions/infusion related reactions (ISR/IRR) were evaluated in relation to the presence of ADAb. Data suggested that the development of ADAb is associated with reduced clinical efficacy and increased incidence of ISR/IRR in patients with RA.

Radiographic data from 1,263 patients participating in the studies were collected and grouped based on patient’s disease activity state at the time of the primary endpoint assessment (Week 24 or Week 30). Radiographic progression was measured using the modified Total Sharp Score (mTSS) at Week 0 and Week 52 or Week 54. Overall, radiographic progression was minimal and comparable across all treatment groups. In addition, the pooled biosimilar group tended to have a lower mean change in mTSS compared with the pooled reference group, which slows down the progression of this disease.

Since the European Commission granted marketing authorization for BENEPALI and FLIXABI in 2016, the two biosimilars have treated nearly 80,000 patients across 23 countries.i In addition, Samsung Bioepis and Biogen expect to launch IMRALDI in Europe in October 2018 and, as a result, are on track to be the first in the industry to bring biosimilars referencing products for all three first-generation anti-TNF therapies to European patients and healthcare systems.

The two abstracts being presented at EULAR 2018 are as follows:

  • Abstract #THU0201 – A pooled analysis of three TNF-A inhibitor biosimilar studies in patients with rheumatoid arthritis comparing radiographic progression by disease activity states [Poster session: June 14, 2018 at 11:45]
  • Abstract #THU0184 – Impact of immunogenicity on clinical efficacy and administration related reaction in TNF inhibitors: a pooled-analysis from three biosimilar studies in patients with rheumatoid arthritis [Poster tour: June 14, 2018 at 12:10]

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six late-stage candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

About Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – TwitterLinkedInFacebookYouTube.

Biogen Safe Harbor

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 about the results from the three Phase III studies of BENEPALI, FLIXABI and IMRALDI; the potential benefits, effects, safety and efficacy of BENEPALI, FLIXABI and IMRALDI; and planning and timing for commercial launch of IMRALDI; and the potential of Biogen’s commercial business and pipeline programs, including BENEPALI, FLIXABI and IMRALDI. These statements may be identified by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including the risk that unexpected concerns may arise from additional data or analysis, or regulatory authorities may require additional data or information or further studies, or may fail to approve, or refuse to approve, or may delay approval of our biosimilar drug candidates risks related to our dependence on third parties for the development and commercialization of biosimilars; risks of legal actions, regulatory scrutiny or other challenges to biosimilars; the risks of other unexpected hurdles; uncertainty of success in commercialization of IMRALDI, which may be impacted by, among other things, the level of preparedness of healthcare providers to treat patients, difficulties in obtaining or changes in the availability of reimbursement for IMRALDI, the effectiveness of sales and marketing efforts, problems with the manufacturing process for IMRALDI, the occurrence of adverse safety events, failure to obtain regulatory approvals in other jurisdictions, failure to protect intellectual property and other proprietary rights, product liability claims, and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

i Biogen data on file

Contact information

MEDIA CONTACT:
Samsung Bioepis
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com
or
Biogen
David Caouette – U.S.
Silvia Dobry – E.U./International
+1 781 464 3260
public.affairs@biogen.com
publicaffairs.eu@biogen.com
or
INVESTOR CONTACT:
Biogen
Matt Calistri
+1 781-464-2442
IR@biogen.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI for Pivotal Study Patients18.6.2019 10:00:00 CESTPressemelding

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration (“FDA”) approved the use of full-body magnetic resonance imaging (“MRI”) using 1.5 Tesla MRI scanners for clinical study patients implanted with the Axonics System. The approval was a result of a supplement filed by Axonics with the FDA under the Investigational Device Exemption (“IDE”) regarding the Company’s ARTISAN-SNM 129-patient pivotal clinical study. The FDA concluded that Axonics provided sufficient data to support full-body MRIs. Raymond W. Cohen, CEO of Axonics, commented, “Allowing full-body MRI scans for our clinical study patients means that none will have to undergo an explant of their neurostimulator device should they require an MRI. We view this as a very positive step by the FD

Norsk Titanium Receives Airbus Contract for Qualification and Production18.6.2019 10:00:00 CESTPressemelding

Officials with Norsk Titanium (Norsk) announce today a contract award from Airbus for the Qualification and Serial Production of the first parts to be manufactured utilizing wire-based Direct Energy Deposition (DED) additive manufacturing technology. “We have worked closely with Airbus over several years to demonstrate the technological maturity and the industrial readiness of our Rapid Plasma Deposition™ (RPD™) process,” said Norsk President and CEO Michael Canario. “This contract award is structured to enable long-term, serial production immediately following qualification. Our Plattsburgh, New York facility, with the assistance of Airbus technical leadership, has been preparing for this moment and is eager to demonstrate a 21st century advanced additive manufacturing capability.” This qualification of Airbus parts will demonstrate the suitability of the DED additive manufacturing process for aircraft structural parts. It will formalize the process by which individual parts are produ

Innovusion Announces Its High-Resolution Image-Grade LiDAR System “Cheetah”, Enabling the Safest Performance in the Vehicle Mobility Industry18.6.2019 09:00:00 CESTPressemelding

Innovusion Inc., the worldwide leader in the design and development of innovative hybrid Solid State LiDAR systems for vehicle safety applications, has announced the availability of its Cheetah system. Based on its innovative rotating polygon optical architecture, Innovusion has melded together proprietary detector electronics, advanced optics and sophisticated software algorithms to offer a system that has no equal in the long-distance, high-resolution LiDAR vehicle mobility system industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190618005066/en/ Innovusion's Cheetah long-distance LiDAR System...the safest in the mobility safety industry (Graphic: Business Wire) Smart architecture, streamlined optics design, and integrated optical paths result in rapid manufacturing, scalability into automotive production, and lower cost. The ability to provide a detection range of 200 meters on objects with 10% reflectivity and cle

You Bank the Digital Asset Banking Platform Presents at UNCHAIN 2019 in Berlin18.6.2019 08:25:00 CESTPressemelding

The Blockchain Conference UNCHAIN 2019 was held in Berlin, Germany, from June 14 to 15, 2019. You Bank, a digital asset banking platform, attended and delivered a speech at the conference. You Bank has henceforth made a brilliant appearance in the European market and officially opened the prelude of the global layout! You Bank’s Digital Asset Banking Platform, the Federal Reserve of the Digital World You Bank, a world-class multinational blockchain financial service platform, is a well-deserved global leader in the field of digital asset management. Headquartered in Singapore, You Bank was founded by the Richmond family, one of the nine Jewish families known as the "Rothschild" family in the digital world. You Bank Global CEO Daniel attended and delivered a speech at the conference. He introduced that the original intention of You Bank was to establish a digital bank which could operate world-widely in the digital economy era. You Bank will cover digital asset management, digital asset

Temenos Successfully Delivers a Single, State-of-the-Art Digital Platform for ABN AMRO’s Private and Corporate Banking Business18.6.2019 08:00:00 CESTPressemelding

Temenos (SIX: TEMN), the banking software company, today announced that ABN AMRO has gone live with Temenos’ WealthSuite digital banking platform, which will power the bank’s international operations for private and corporate banking. The shift to a single shared digital banking platform will allow ABN AMRO to reduce IT operational costs and achieve an improved cost/ income ratio. The open digital banking platform will future-proof ABN AMRO’s growth and enable the bank to deliver innovative and personalized products and services faster to market. Belgium is the first international branch to go live with the Temenos solution under ABN AMRO’s rollout plan, which will see the bank migrate two additional countries on the new platform in the coming years. ABN AMRO joins the growing list of top tier banks that have deployed Temenos WealthSuite to transform their wealth management operations. With Temenos WealthSuite, ABN AMRO will deploy an end-to-end, highly scalable and configurable platfo

Hansol Paper and Iconex Announce Mutual Decision to Withdraw from Agreement Governing Sale of Schades and R+S to Iconex18.6.2019 08:00:00 CESTPressemelding

Iconex and Hansol Paper announced today that the companies are withdrawing from their definitive agreement signed November 2, 2018, under which Iconex would have acquired Schades and R+S from Hansol Paper. This decision, reached by mutual agreement between the parties, is due to the ruling of The United Kingdom’s Competition and Markets Authority (CMA) to move the approval process for this transaction to Phase 2. This allows the UK CMA an additional six months to reach a decision, which was deemed to be too long of a delay by both parties. The parties believe that the proposed transaction met the relevant legal criteria for approval in the UK, and that it was in the best interests of our customers, employees and the marketplace in the United Kingdom and beyond. This UK CMA decision was unexpected by both parties given that the European Commission cleared the deal earlier this spring. Like elsewhere in Europe, the UK market is highly competitive with a significant number of players. “Th